U.S. Glp-1 Agonists Weight Loss Drugs Market Size & Outlook
Related Markets
U.S. glp-1 agonists weight loss drugs market highlights
- The U.S. glp-1 agonists weight loss drugs market generated a revenue of USD 9,952.8 million in 2024 and is expected to reach USD 37,278.6 million by 2030.
- The U.S. market is expected to grow at a CAGR of 19.4% from 2025 to 2030.
- In terms of segment, semaglutide (wegovy) was the largest revenue generating drug in 2024.
- Tirzepatide (Zepbound) is the most lucrative drug segment registering the fastest growth during the forecast period.
Glp-1 agonists weight loss drugs market data book summary
| Market revenue in 2024 | USD 9,952.8 million |
| Market revenue in 2030 | USD 37,278.6 million |
| Growth rate | 19.4% (CAGR from 2025 to 2030) |
| Largest segment | Semaglutide (wegovy) |
| Fastest growing segment | Tirzepatide (Zepbound) |
| Historical data | 2018 - 2023 |
| Base year | 2024 |
| Forecast period | 2025 - 2030 |
| Quantitative units | Revenue in USD million |
| Market segmentation | Semaglutide (Wegovy), Liraglutide (Saxenda), Tirzepatide (Zepbound), Other Drugs |
Other key industry trends
- In terms of revenue, U.S. accounted for 71.9% of the global glp-1 agonists weight loss drugs market in 2024.
- Country-wise, U.S. is expected to lead the global market in terms of revenue in 2030.
- In North America, U.S. glp-1 agonists weight loss drugs market is projected to lead the regional market in terms of revenue in 2030.
- U.S. is the fastest growing regional market in North America and is projected to reach USD 37,278.6 million by 2030.
No credit card required*
Horizon in a snapshot
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
GLP-1 Agonists Weight Loss Drugs Market Scope
GLP-1 Agonists Weight Loss Drugs Market Companies
| Name | Profile | # Employees | HQ | Website |
|---|---|---|---|---|
| Eli Lilly and Company | View profile | - | - | - |
| Structure Therapeutics | View profile | 101-250 | South San Francisco, California, United States, North America | https://structuretx.com/ |
| Viking Therapeutics Inc | View profile | 28 | 9920 Pacific Heights Boulevard, Suite 350, San Diego, CA, United States, 92121 | https://www.vikingtherapeutics.com |
| Novo Nordisk A/S ADR | View profile | 66015 | Novo Alle 1, Bagsvaerd, Denmark, 2880 | https://www.novonordisk.com |
| Pfizer Inc | View profile | 88000 | 66 Hudson Boulevard East, New York, NY, United States, 10001-2192 | https://www.pfizer.com |
U.S. glp-1 agonists weight loss drugs market outlook
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to glp-1 agonists weight loss drugs market will help companies and investors design strategic landscapes.
Semaglutide (wegovy) was the largest segment with a revenue share of 93.49% in 2024. Horizon Databook has segmented the U.S. glp-1 agonists weight loss drugs market based on semaglutide (wegovy), liraglutide (saxenda), tirzepatide (zepbound), other drugs covering the revenue growth of each sub-segment from 2018 to 2030.
In the U.S., the GLP-1 agonists weight loss drugs market leads North America, capturing 95.23% of the regional market share in 2024.
Semaglutide and Tirzepatide have gained significant popularity due to their effectiveness in weight loss, with widespread distribution through hospital pharmacies and retail pharmacies. Additionally, the oral formulations of these drugs are gaining traction, making them more accessible to a broader patient base.
Reasons to subscribe to U.S. glp-1 agonists weight loss drugs market databook:
-
Access to comprehensive data: Horizon Databook provides over 1 million market statistics and 20,000+ reports, offering extensive coverage across various industries and regions.
-
Informed decision making: Subscribers gain insights into market trends, customer preferences, and competitor strategies, empowering informed business decisions.
-
Cost-Effective solution: It's recognized as the world's most cost-effective market research database, offering high ROI through its vast repository of data and reports.
-
Customizable reports: Tailored reports and analytics allow companies to drill down into specific markets, demographics, or product segments, adapting to unique business needs.
-
Strategic advantage: By staying updated with the latest market intelligence, companies can stay ahead of competitors, anticipate industry shifts, and capitalize on emerging opportunities.
Target buyers of U.S. glp-1 agonists weight loss drugs market databook
-
Our clientele includes a mix of glp-1 agonists weight loss drugs market companies, investment firms, advisory firms & academic institutions.
-
30% of our revenue is generated working with investment firms and helping them identify viable opportunity areas.
-
Approximately 65% of our revenue is generated working with competitive intelligence & market intelligence teams of market participants (manufacturers, service providers, etc.).
-
The rest of the revenue is generated working with academic and research not-for-profit institutes. We do our bit of pro-bono by working with these institutions at subsidized rates.
Horizon Databook provides a detailed overview of country-level data and insights on the U.S. glp-1 agonists weight loss drugs market , including forecasts for subscribers. This country databook contains high-level insights into U.S. glp-1 agonists weight loss drugs market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Partial client list
U.S. glp-1 agonists weight loss drugs market size, by route of administration, 2018-2030 (US$M)
U.S. GLP-1 Agonists Weight Loss Drugs Market Outlook Share, 2024 & 2030 (US$M)
Related industry reports
Related statistics
No records
No related statistics found.
Sign up - it's easy, and free!
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
